|

A Noninvasive Breakthrough in Diagnosing Mesothelioma

A Noninvasive Breakthrough in Diagnosing Mesothelioma

Researchers from Sweden think that noninvasive immunohistochemical (IHC) analysis can correctly diagnose mesothelioma.

This could be helpful to doctors who want to look for mesothelioma in their patients. It can be hard to diagnose mesothelioma and doctors often need to use invasive methods to reach a diagnosis.

An Accurate Mesothelioma Diagnosis

Mesothelioma is a rare cancer, and the symptoms usually look like other, more common, diseases. Because of this, doctors struggle to identify mesothelioma in their patients.

Symptoms typically include fatigue, shortness of breath, abdominal pain, and coughing. The symptoms are caused by cancerous cells that develop due to a person’s exposure to asbestos.

To diagnose mesothelioma, a doctor will first perform a history and physical. The history involves learning about when the symptoms started. It also includes any mesothelioma risk factors you might have, such as exposure to asbestos. For the physical, the doctor will look at your body for signs of illness.

If the doctor thinks that mesothelioma might be a possible diagnosis, they will need to run more tests. These may include imaging tests, removing fluid for testing, a biopsy, and other procedures. Some of these tests, like a biopsy, can be invasive and painful.

The Potential of Immunohistochemical Analysis for Mesothelioma

IHC analysis is a way to test the fluid around the possible cancer site for mesothelioma biomarkers. The procedure to collect the fluid is simple and noninvasive. IHC analysis can give the doctor important information. This is especially important when looking at tissue samples is not possible.

For this study, the researchers compared 59 pairs of tissue samples and fluid samples from patients with mesothelioma. The researchers ran the IHC analysis on the fluid samples. They found that it was accurate at diagnosing mesothelioma over 90% of the time.

The researchers recommend more studies to look at this method for diagnosing mesothelioma. Further research can help to improve the accuracy of IHC analysis at diagnosing this disease.

Source

Mansour MSI, Huseinzade A, Seidal T, et al. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma [published online ahead of print, 2023 Jun 19]. Cytopathology. 2023;10.1111/cyt.13265. doi:10.1111/cyt.13265. https://pubmed.ncbi.nlm.nih.gov/37337638/

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…